Logo image
Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis
Journal article   Open access   Peer reviewed

Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis

Cecilia M. Prele, Tylah Miles, David R. Pearce, Robert J. O'Donoghue, Chris Grainge, Lucy Barrett, Kimberly Birnie, Andrew D. Lucas, Svetlana Baltic, Matthias Ernst, …
The European respiratory journal, Vol.60(5), 2101469
2022
PMCID: PMC9684624
PMID: 35798357
pdf
Published1.46 MBDownloadView
Published (Version of Record)CC BY-NC V4.0 Open Access

Abstract

Life Sciences & Biomedicine Respiratory System Science & Technology
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with chronic inflammation and tissue remodelling leading to fibrosis, reduced pulmonary function, respiratory failure and death. Bleomycin (Blm)-induced lung fibrosis in mice replicates several clinical features of human IPF, including prominent lymphoid aggregates of predominantly B-cells that accumulate in the lung adjacent to areas of active fibrosis. We have shown previously a requirement for B-cells in the development of Blm-induced lung fibrosis in mice. To determine the therapeutic potential of inhibiting B-cell function in pulmonary fibrosis, we examined the effects of anti-CD20 B-cell ablation therapy to selectively remove mature B-cells from the immune system and inhibit Blm-induced lung fibrosis. Anti-CD20 B-cell ablation did not reduce fibrosis in this model; however, immune phenotyping of peripheral blood and lung resident cells revealed that anti-CD20-treated mice retained a high frequency of CD19+ CD138+ plasma cells. Interestingly, high levels of CD138+ cells were also identified in the lung tissue of patients with IPF, consistent with the mouse model. Treatment of mice with bortezomib, which depletes plasma cells, reduced the level of Blm-induced lung fibrosis, implicating plasma cells as important effector cells in the development and progression of pulmonary fibrosis.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Metrics

1 File views/ downloads
69 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.208 Vasculitis & Autoimmune Disorders
1.208.1262 Idiopathic Pulmonary Fibrosis
Web Of Science research areas
Respiratory System
ESI research areas
Clinical Medicine
Logo image